In the BioHarmony Drug Report Database
Abemaciclib
Verzenio, Verzenios (abemaciclib) is a small molecule pharmaceutical. Abemaciclib was first approved as Verzenio on 2017-09-28. It has been approved in Europe to treat breast neoplasms. It is known to target cyclin-dependent kinase 6 and cyclin-dependent kinase 4. Verzenio’s patent is valid until 2029-12-15 (FDA).
Trade Name
|
Verzenios |
|---|---|
Common Name
|
abemaciclib |
ChEMBL ID
|
CHEMBL3301610 |
Indication
|
breast neoplasms |
Drug Class
|
Cyclin dependent kinase inhibitors |
Image (chem structure or protein)